Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coagulation factors V, VIII, XI, and XIII are a specific group of proteins within the blood coagulation cascade that are primarily activated by thrombin (Factor IIa) to amplify and stabilize the formation of a blood clot [5, 6, 9]. Factors V (Proaccelerin) and VIII (Antihemophilic factor) function as essential non-enzymatic cofactors that dramatically accelerate the activation of prothrombin and factor X, respectively, facilitating a rapid burst of thrombin generation [1, 3, 10]. Factor XI (Plasma thromboplastin antecedent) is a serine protease that sustains this process through a feedback loop in the intrinsic pathway, while Factor XIII (Fibrin-stabilizing factor) is a transglutaminase that cross-links fibrin strands to provide mechanical stability and resistance to fibrinolysis [1, 13, 14, 17]. Deficiencies in these factors are associated with significant bleeding disorders, most notably Hemophilia A (Factor VIII deficiency) and Hemophilia C (Factor XI deficiency), which are managed through replacement therapies or bypass agents [1, 10]. Conversely, these factors—particularly Factor XI—have become major targets for next-generation anticoagulants, such as abelacimab and milvexian, which aim to prevent pathological thrombosis with a significantly lower risk of bleeding compared to traditional anticoagulants [2, 7, 13, 18]. The therapeutic landscape for these factors continues to evolve, with a focus on improving safety profiles and reducing the burden of treatment for patients with both hereditary deficiencies and thrombotic risks [7, 12, 15].
Replacement of deficient coagulation factors, inhibition of protease activity to prevent thrombus formation, and mimetic activity to substitute for missing cofactors.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coagulation factor V (F5), Coagulation factor VIII (F8), Coagulation factor XI (F11), and Coagulation factor XIII (F13) (F5, F8, F11, F13).